Post by Merck Group

Exciting news! Today, we opened a new €25 million BioReliance® testing facility at our global headquarters in Darmstadt, Germany. The facility expands access to commercial drug substance and drug product release testing as well as stability testing for biopharmaceutical companies developing and commercializing therapies in Europe. The 2,000-square-meter facility is designed to help customers meet European requirements for in-region drug substance and drug product release testing and expands our ability to support customers from drug development through commercialization. The site will also offer Good Manufacturing Practice (GMP)-compliant stability studies for monoclonal antibodies and cell therapies, addressing the growing demand for biologics testing across Europe. The facility will employ a growing team with headcount projected to expand significantly over the next few years to support client demand, and is strategically positioned to support biopharmaceutical companies seeking to release drug products into European markets. Find out more here: http://ms.spr.ly/6045v2RZZ Merck Life Science